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INFLAMMATION of the rat distal intestine was induced by
intradermal sensitization and subsequent multiple intra-
jejunal challenge with the hapten 2,4,6-trinitrobenzene-
sulphonic acid (TNBS) via an implanted catheter. The
time course of the inflammatory reaction was followed by
determination of the enteritis score and measurement of
in vitro eicosanoid formation of homogenates of the gut
after 0, 1, 2, 4, 7, 14 and 21 days of local daily challenge
with 0.08% TNBS. There was a small initial increase of
eicosanoid formation, reached at days 1 and 2, followed
by a significant increase in metabolism of arachidonic acid
on day 21. Although at day 1 a four-fold increase in
inflammation score was reached, no further significant
changes were observed during the following 3 weeks. The
greatest increase in metabolite formation was observed in
prostanoids TxB2, PGE. and PGDz and the 5-1ipoxygenase
product LTC4, whereas minor changes were found for
LTB and other lipoxygenase products such as 12- and
15-HETE. The formation of these metabolites was already
inhibited by low-dose 5-aminosalicylic acid (5-ASA),
given orally twice daily during the 3 weeks challenge
period, while the enteritis score was affected dose-
dependently.
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Introduction
Ulcerative colitis and Crohn’s disease represent
two entities of inflammatory disease of the large and
small intestine whose aetiology and inter-relation-
ships are not yet known. Their course is both acute
and chronic, with unpredictable remissions and
exacerbations, many local and systemic complica-
tions, and variable response to therapy. Progress
in understanding the pathogenesis of ulcerative
colitis and Crohn’s disease has been hampered by
the intrinsic complexity of the diseases and their
variable manifestations, which serve to make the
distinction between essential and non-essential
features difficult. Another important limitation in
the study and understanding of the diseases has
been the lack of suitable animal models.2
Despite this, immunoregulation and lymphocyte
function in patients with ulcerative colitis has been
reported to be abnormal, suggesting that it may be
an autoimmune disorder.>s Moreover metabolites
of arachidonic acid seem to be implicated in the
pathogenesis of inflammatory bowel diseases.
Cyclooxygenase as well as lipoxygenase metabolites
have been reported to be increased in patients with
ulcerative colitis or Crohn’s disease.6-9 The
anti-inflammatory properties of prostaglandin E2
(PGE2) are well described,1 in contrast to the
pro-inflammatory action of leukotriene B4 (LTB4)
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whereas several eicosanoids are involved in the
feed-back mechanisms of the arachidonic acid
cascade. In the present study the metabolism of
arachidonic acid in inflamed mucosal tissue taken
from an animal model of inflammatory bowel
disease (IBD) was investigated in order to
elucidate further the involvement of arachidonic
acid metabolites in inflammatory bowel disease. In
a previous study, it was shown that the level of ex
vivo released immunoreactive LTB4 was elevated in
inflamed distal small intestine taken from rats with
TNBS-induced chronic enteritis. In the present
study the balance between cyclooxygenase and
lipoxygenase metabolites formed by rat distal small
intestine has been investigated. Furthermore, the
validity of this model was investigated by
examining the effects of 5-aminosalicylic acid
(5-ASA), on both the enteritis score and the ratio
of pro- and anti-inflammatory products formed.
Materials and Methods
Induction of enteritis: Inflammation of the rat distal
small intestine was induced by a method previously
described in detail. 1’2 Female rats (150-200 g) were
sensitized by intradermal injection of 0.05 ml of
0.8% 2,4,6-trinitrobenzenesulphonic acid (TNBS)
into their back once daily for 3 consecutive days.
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After 18 days the animals received a further
intradermal booster injection (0.05 ml). After a
further 10 days the animals were challenged once
daily for 21 consecutive days by intrajejunal
application of a 0.08% TNBS preparation (0.2 mg/
rat) via an implanted catheter. Drug treatment with
5-ASA (4.64, 10.0, 21.5 and 46.4 mg/kg/day;
Heraeus, Karlsruhe, Germany) was performed by
oral application twice a day starting 6 h before the
first local TNBS administration and was continued
for 3 weeks, the last drug application being
performed 6 h before the last TNBS administration.
5-ASA was suspended in 1% carboxymethylcellu-
lose. Each group consisted of ten rats.
Working-up method of distal small intestine" Rats were
killed by COg asphyxiation 24 h after the last
intraluminal application of TNBS at day 0, 1, 2, 4,
7, 14 and 21. The distal 10 cm of small intestine
were dissected out and immediately assessed by two
independent observers for inflammation using a
macroscopic enteritis score of value 0-3, defined as
no (0), slight (1), intermediate (2) or intense (3)
redness of the intestine. 11’12 Segments of precisely
10cm were rinsed in saline and weighed as a
parameter of oedema or granuloma formation.
Segments of inflamed and control distal small
intestine were histologically examined for qualita-
tive confirmation of the visual assessment of
inflammation.
Eicosanoid metabolism and determinations: To determine
eicosanoid reduction of the inflamed mucosa, tissue
samples of distal small intestine were homogenized
in Krebs’ buffer by means of an Ultra-Turrax,
incubated for 10min with 0.125/.tCi [14C]-
arachidonic acid and stimulated with Ca-ionophore
A23187 (2/.tM). 9 The 14C-labelled eicosanoids
formed were separated by HPLC and measured by
on-line beta detection.3 Total protein content of
any tissue sample was determined.4
Data handling: Data obtained by comparison of
enteritis score, gut weight, protein content and
formation of arachidonic acid metabolites, ex-
pressed as mean-+-S.E.M, of ten experiments
per group, were statistically analysed by Mann-
Whitney U-test; values of p _< 0.05 being con-
sidered as significant.
Results
Enteritis score: A rapid increase of the enteritis
score was observed from day 0 to day 2, which
did not further increase until day 21 of daily
intrajejunal treatment with TNBS (Table 1).
Histological examination of the gut samples
confirmed the results obtained by macroscopic
enteritis score. Remarkable changes in mucosal
Table 1. Enteritis score before and
several times after local TNBS admin-
istration and 5-ASA treatment (n 10)
Days after TNBS Enteritis score
0 0.5 +_ 0.02
2.1 _+ 0.10
2 2.2 _+ 0.08
4 2.1 +_0.06
7 1.9+_0.11
14 2.0 _+ 0.06
21 2.3 _+ 0.08
5-ASA (mg/kg)
after 21 days TNBS Enteritis score
4.64 1.7 _+ 0.12*
10.0 1.6 +_ 0.13"
21.5 1.2 +_ 0.12*
46.4 1.1 +_ 0.07*
*p < 0.01 vs day 21 of non-treated rats.
integrity and activation of Peyer’s patches were
induced. There was no significant difference
between the TNBS groups from day 2 to day 14
of local TNBS treatment. Acute inflammatory
response with a predominantly neutrophil infiltra-
tion was not detectable. The histology showed light
to moderate signs of chronic inflammation with
infiltration of mainly lymphocytes and histiocytes.
Body weight: Body weights were not significantly
changed during intrajejunal implantation, TNBS
challenge or 5-ASA treatment.
Gut weight: Gut weights of all 10 cm samples were
similar during the time course of TNBS treatment
within a range of 0.78 to 0.95 g/10 cm distal small
intestine. No significant difference was observed
between the different groups (data not shown).
Protein content: Protein content of all tissue samples
taken from distal small intestine after different times
of intrajejunal TNBS treatment was constant within
a range of 11.8 to 14.2/.tg/mg tissue and no
significant differences were observed between the
different groups (data not shown).
Arachidonic acd metabolite profile: The main results in
determination of the time course of arachidonic acid
metabolism were: (1) a slight increase of overall
eicosanoid production after 1 day of TNBS
treatment; (2) no change of metabolism after 1 to
14 days of intrajejunal TNBS treatment; and (3) a
marked increase of eicosanoids after 21 days of
TNBS treatment.
The greatest increase of eicosanoids was
observed in the formation of TxB2, PGD2 and
sulphidopeptide leukotrienes (S-LTs) (25-30-fold
compared to controls, Figs 1, 2 and 3). Smaller
increases were found for the PGE2 (10-fold),
6kPGF, LTB4, 12- and 15-HETE (5-fold
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FIG. 1. Production of r14C]-arachidonic acid derived cyclooxygenase
metabolites 6kPGFI= and TxB2 (expressed as dpm/#g protein) by distal
small intestine homogenates of rats treated with local TN BS for different
time periods (0, 1,2, 4, 7, 14 and 21 days) and (pre)treated with 5-ASA
(4.64 mg/kg/day) after local TNBS for 21 days (A). n 10; *p < 0.05 vs
t= 0. r--I, 6kPGFI=; [], TxB2.
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FIG. 3. Production of [14C]-arachidonic acid derived 5-1ipoxygenase
metabolites sulphidopeptide LTs (S-LTs LTC4 + LTD4) and LTB4 (ex-
pressed as dpm/#g protein) by distal small intestine homogenates of rats
treated with local TNBS for different time periods (0, 1,2, 4, 7, 14 and 21
days) and (pre)treated with 5-ASA (4 mg/kg/day) after local TNBS for
21 days (A). n 10; *p < 0.05 vs 0. I-1, S LTs; [], LTB4.
increase; Figs 1-4). No changes were observed in
HHT, 5-HETE, and 8-HETE formation (data not
shown).
Effects of5-ASA Oral treatment of the animals with
5-ASA dose-dependently reduced the enteritis score
after 21 days of intraluminal application of TNBS
(Table 1). Gut weight of distal small intestine of a
defined length of 10 cm was slightly reduced by
5-ASA treatment. Both the increased cyclo-
oxygenase and lipoxygenase production after
21 days of TNBS application was diminished to
40% of the production by 5-ASA treatment (see
Figs 1-4, A-marked bars) still being a 2-4-fold
increase compared to control values on day 0.
Discussion
In this study the authors found an increase in the
metabolism of arachidonic acid by homogenates of
inflamed distal small intestine taken from rats
100
75
25 I *0
0 2 4 7 14 21 A
Time (days)
FIG. 2. Production of [C]-arachidonic acid derived cyclooxygenase
metabolites PGE2 and PGD2 (expressed as dpm/#g protein) by distal
small intestine homogenates of rats treated with local TN BS for different
time periods (0, 1,2, 4, 7, 14 and 21 days) and (pre)treated with 5-ASA
(4.64 mg/kg/day) after local TNBS for 21 days (A). n 10; *p < 0.05 vs
t= 0. 1--], PGE2; [], PGD2.
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FIG. 4. Production of [14C]-arachidonic acid derived 12- and 15-
lipoxygenase metabolites 12- H ETE and 15- H ETE (expressed as dpm/#g
protein) by distal small intestine homogenates of rats treated with local
TNBS for different time periods (0, 1, 2, 4, 7, 14 and 21 days) and
(pre)treated with 5-ASA (4.64 mg/kg/day) after local TNBS for 21 days
(A). n= 10; *p < 0.05 vs t=0. I-I, 15-HETE; D, 12-HETE.
during chronic enteritis induced by the chemical
hapten TNBS. In previous studies marked species
differences in the production pattern of eicosanoids
by inflammatory cells was shown, is These differ-
ences also occur in inflamed and non-inflamed
colonic tissue. 16 In human inflammatory bowel
disease mainly PGE2 and LTB4 were measured in
dialysis ftuid,17 whereas lately evidence was obtained
that other lipoxygenase products, such as 15-
HETE, are important mediators of inflammation.9
It is known that prostacyclin and 15-HETE are
formed by endothelial cells. Probably during the
type of inflammation used in this study these cells
are not triggered to increase eicosanoid synthesis.
The prostaglandins LTC4 and LTB4 normally are
formed by macrophages, eosinophils and mast cells
respectively. 18 Thromboxane, however, is mainly
formed by platelets and macrophages.s In human
colitis TXB2 formation was not increased sig-
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nificantly in colonic mucosa,9 whereas in experi-
mental colitis marked elevation of thromboxane
synthesis was only observed in rabbits after the
induction of dinitrochlorobenzene (DNCB)8’19 and
formyl-methionyl-leucyl-phenylalanine (FMLP).2
In acute inflammation a rapid influx of granulocytes
is seen, followed by inflammatory cells such as
macrophages. Although in histological sections the
contribution of platelets was negligible, one should
consider the potency of platelets in generating
thromboxane.
Despite the variation of the different types of
metabolites determined in this investigation follow-
ing the time course, the results suggest a break-even
point between 14 and 21 days of local intraluminal
TNBS treatment. However, this does not correlate
with the observed changes in enteritis score and
histological assessment of the distal small intestine
after different times of TNBS treatment.
According to the normal time course of
inflammatory reactions an early response char-
acterized by acute inflammation and a late response
characterized by chronic inflammation were ex-
pected during the time course of TNBS treatment.
This was partly supported by the small initial
increase in mediators and the exacerbation of
mediator production after 21 days. This observa-
tion, however, was not confirmed by histologic
observations as there was no detectable infiltration
of neutrophils that would indicate an acute
inflammatory response. The onset of inflammation
on day 2 of TNBS treatment was characterized by
infiltration of lymphocytes and histiocytes, indica-
ting chronic inflammatory response directly after
TNBS treatment. These results are somewhat
unexpected, and future studies should include
examination of changes in the first hours of local
TNBS treatment.
In contrast to other immunologically induced
chronic inflammation of the gut as animal models
of IBD,8’21-26 chronicity of the inflammatory
reaction in this model was induced by multiple
instead of one21 or few22’25’26 local administrations
of the immunogen. Another difference is a 3-week
instead of 3-day22’25’26 time schedule for the local
challenge procedure. This repeated and weak
stimulation of the immune system by one specific
immunogen may mimic the human disease more
closely, and the model has more features in common
with human IBDs than non-immunological and
acute models.27 In contrast to the human disease the
typical discontinuous time course and the mixture
of chronic and acute inflammation28 were not
induced in this model.
Oral 5-ASA (low dose, 4.64 mg/kg/day) during
the 21-day TNBS treatment schedule clearly
reduced eicosanoid formation, but resulted in only
a slight decrease of approx. 15% in histological
examination and symptom score. The enteritis
score, however, was dose-dependently decreased
(Table 1), while a further inhibition of eicosanoid
synthesis was not observed. An explanation for this
could be that only a weak dose of 5-ASA is
sufficient to influence AA metabolism, but that
much higher doses are needed to counteract the
severe signs of inflammation as was reflected in the
macroscopic inflammation score. The time schedule
of 5-ASA treatment in this investigation includes
the whole time period of enteritis induction by local
TNBS administration. In order to answer the
question of whether 5-ASA is effective on early or
established inflammatory response of the distal
small intestine in this model, further investigations
with different time schedules of 5-ASA treatment
have to be performed.
In conclusion, although this model has many
features of Crohn’s disease, it is still not clear
whether it is suitable for testing new drugs in IBD,
especially those which are supposed to act as
inhibitors of the arachidonic acid metabolism.
These present findings indicate that eicosanoids are
important mediators in the chronic phase of
inflammatory bowel disease,29 probably in the
regulation of the release of pro-inflammatory
substances such as platelet activating factor (PAF),3
cytokines,31 LTB432 and LTD4 .33 Further invest-
igations with the use of nonspecific acting
anti-inflammatory drugs, such as corticosteroids,
could give more information about this sequential
release of inflammatory mediators.
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